Literature DB >> 26342166

Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS/MS and its application in drug tissue distribution study.

Xiao-wei Xu1, Xin-juan Su1, Yu-niao Zhang2, Xiao-kang Zheng2, Peng-fei Lv2, Jie Hu3.   

Abstract

A sensitive and rapid ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed to simultaneous determine nintedanib and BIBF 1202 in mice plasma and tissue using carbamazepine as the internal standard (IS). Sample preparation was accomplished through a protein precipitation procedure with acetonitrile. The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7μm) with the mobile phase of acetonitrile and 0.1% formic acid in water with gradient elution at a flow rate of 0.40mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer equipped with electrospray ionization (ESI) by multiple reactions monitoring (MRM) of the transitions at m/z 540.3→113.1 for nintedanib, m/z 526.3→113.1 for BIBF 1202 and m/z 237.1→194.1 for IS, respectively. The linearity of this method was found to be within the concentration range of 1-1000ng/mL with a lower limit of quantification of 1.0ng/mL for each drug. Only 3.0min was needed for an analytical run. The inter-day and intra-day precision and accuracy of quality control (QC) samples, evaluated both in plasma and tissue homogenates, were all within 15%. The method was successfully applied to the pharmacokinetic and tissue distribution study of nintedanib and BIBF 1202 in mice after oral administration of nintedanib.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BIBF 1202; Nintedanib; Pharmacokinetics; Plasma; Tissue distribution; UPLC–MS/MS

Mesh:

Substances:

Year:  2015        PMID: 26342166     DOI: 10.1016/j.jchromb.2015.08.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  An integrated strategy for comprehensive characterization of metabolites and metabolic profiles of bufadienolides from Venenum Bufonis in rats.

Authors:  Wen-Long Wei; Hao-Jv Li; Wen-Zhi Yang; Hua Qu; Zhen-Wei Li; Chang-Liang Yao; Jin-Jun Hou; Wan-Ying Wu; De-An Guo
Journal:  J Pharm Anal       Date:  2021-02-12

2.  A Sample and Sensitive HPLC-MS/MS Method for Simultaneous Determination of Ziyuglycoside I and Its Metabolite Ziyuglycoside II in Rat Pharmacokinetics.

Authors:  Zhi-Feng Li; Meng-Ying Zhou; Ting Tan; Chen-Cong Zhong; Qi Wang; Ling-Ling Pan; Ying-Ying Luo; Shi-Lin Yang; Yu-Lin Feng; Hui Ouyang
Journal:  Molecules       Date:  2018-02-28       Impact factor: 4.411

3.  Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.

Authors:  Bernhard Englinger; Sebastian Kallus; Julia Senkiv; Daniela Heilos; Lisa Gabler; Sushilla van Schoonhoven; Alessio Terenzi; Patrick Moser; Christine Pirker; Gerald Timelthaler; Walter Jäger; Christian R Kowol; Petra Heffeter; Michael Grusch; Walter Berger
Journal:  J Exp Clin Cancer Res       Date:  2017-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.